METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT
The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.
1 . A method of treating ulcerative colitis in a patient in need of such treatment, said patient having been previously administered a composition comprising 5-aminosalicylic acid, said method comprising administering to said patient a second composition in the form of a single tablet, said single tablet comprising about 9 mg of budesonide.
2 . A method according to claim 1 , wherein said second composition is administered to said patient for up to 8 weeks or a portion thereof.
3 . A method according to claim 1 , wherein said patient has a UCDAI score of greater than or equal to 4 prior to said second composition being administered to said patient.
4 . A method according to claim 3 , wherein second composition is administered to said patient once daily for up to 8 weeks or a portion thereof.
5 . A method according to claim 4 , wherein after said treatment, said UCDAI score for said patient is less than or equal to 1.
6 . A method according to claim 1 , wherein said patient is experiencing an ulcerative colitis flare prior to said second composition being administered to said patient.
7 . A method according to claim 6 , wherein said second composition is administered to said patient once daily for up to 8 weeks or a portion thereof.
8 . A method according to claim 7 , wherein said ulcerative colitis in said patient is in remission after said treatment.
9 . A method of treating ulcerative colitis in a patient in need of such treatment, said method comprising administering to said patient a first and a second composition, said first composition comprising 5-aminosalicylic acid and said second composition is in the form of a single tablet, said single tablet comprising about 9 mg of budesonide.
10 . A method according to claim 9 , wherein said second composition is administered to said patient for up to 8 weeks or a portion thereof.
11 . A method according to claim 9 , wherein said patient has a UCDAI score of greater than or equal to 4 prior to said second composition being administered to said patient.
12 . A method according to claim 11 , wherein said second composition is administered to said patient once daily for up to 8 weeks or a portion thereof.
13 . A method according to claim 12 , wherein after said treatment, said UCDAI score for said patient is less than or equal to 1.
14 . A method according to claim 9 , wherein said patient is experiencing an ulcerative colitis flare prior to said second composition being administered to said patient.
15 . A method according to claim 14 , wherein second composition is administered to said patient once daily for up to 8 weeks or a portion thereof.
16 . A method according to claim 15 , wherein said ulcerative colitis in said patient is in remission after said treatment.
17 . A method according to claim 9 , wherein said first composition and said second composition are administered to said patient simultaneously.
18 . A method of treating ulcerative colitis in a patient in need of such treatment, said patient having been previously administered a composition comprising 5-aminosalicylic acid, said method comprising administering to said patient a first composition and a second composition, said first composition comprising 5-aminosalicylic acid and said second composition is in the form of a single tablet, said single tablet comprising about 9 mg of budesonide.
19 . A method according to claim 18 , wherein second composition is administered to said patient for up to 8 weeks or a portion thereof.
20 . A method according to claim 19 , wherein said patient has a UCDAI score of greater than or equal to 4 prior to said second composition being administered to said patient.
21 . A method according to claim 20 , wherein second composition is administered to said patient once daily for up to 8 weeks or a portion thereof.
22 . A method according to claim 21 , wherein after said treatment, said UCDAI score for said patient is less than or equal to 1.
23 . A method according to claim 18 , wherein said patient is experiencing an ulcerative colitis flare prior to said second composition being administered to said patient.
24 . A method according to claim 23 , wherein second composition is administered to said patient once daily for up to 8 weeks or a portion thereof.
25 . A method according to claim 24 , wherein said ulcerative colitis in said patient is in remission after said treatment.
26 . A method according to claim 18 , wherein said first composition and said second composition are administered to said patient simultaneously.
27 . A method of maintaining remission of ulcerative colitis in a patient in need of such maintenance, said method comprising administering to said patient a composition in the form of a single tablet, said single tablet comprising about 6 mg of budesonide, whereby said remission of ulcerative colitis in said patient is maintained.
28 . A method according to claim 27 , wherein said single tablet comprising about 6 mg of budesonide is administered to said patient once daily for up to 12 months.
29 . A method according to claim 28 , wherein said single tablet comprising about 6 mg of budesonide is administered to said patient once daily for up to 6 months.